Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?

James P. C. CoverdaleThaisa Laroiya-McCarronIsolda Romero-Canelón2024-08-152024-08-152019jz000074-0075https://tustorage.ulb.tu-darmstadt.de/handle/tustorage/7098540Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?Articlehttps://doi.org/10.3390/inorganics7030031